Posters

IO Summit Europe 2024: Fully Human Conditional Agonist 4-1BB×CD40 Bispecific Antibody Exhibits Potent In Vitro and In Vivo Efficacy

  Used in the poster: BsAb Discovery Platform   Summary:  4-1BB and CD40 agonists are promising candidates for cancer immunotherapy but have had limited success…

Read more
Festival of Biologics 2024: Generation of a TAA Antibody Library to Support the Development of Antibody-Drug Conjugates (ADC)

  Used in the poster: Bispecific ADC Platform   Summary:  Biocytogen's antibody discovery team has generated a library of antibodies targeting approximately 200 tumor-associated antigens…

Read more
AACR 2024: Targeting mutant KRAS proteins with novel TCR-mimic fully human antibodies

Used in the poster: TCR-Mimic Antibody Platform Summary:  Novel antibodies highly specific to KRAS mutations (G12V and G12D) presented by human leukocyte antigen (HLA) were…

Read more
AACR 2024: Establishment of a humanized IL5/IL5RA mouse model to evaluate modulators of eosinophilic inflammation in vivo

Used in the poster: B-hIL5/hIL5RA mice Summary: IL-5/IL-5R signaling is crucial for eosinophil function and has therapeutic implications for inflammatory diseases like asthma. We developed…

Read more
AACR 2024: A novel humanized NKP46 mouse model to support xenograft studies evaluating NK cell-based cancer immunotherapies

Used in the poster: B-hNKP46 mice Summary: The NKP46 receptor is vital for NK cell recognition and activation against tumors, making it a target for…

Read more
AACR 2024: Development and validation of humanized HLA mouse model platforms for preclinical evaluation of novel peptide vaccines

Used in the poster: B-HLA-A11.1 mice, B-HLA-A24.2 mice Summary: The HLA class I major histocompatibility complex is crucial for immune surveillance and is being explored…

Read more
AACR 2024: Generation of a novel severely immunodeficient Sprague Dawley rat model for xenograft studies

Used in the poster: B-SDG rats Summary: Rag2 is essential for T and B cell development, while Il2rg is crucial for various immune cell functions.…

Read more
AACR 2024: A novel humanized CD16A model to evaluate efficacy of human antibody therapeutics in triggering ADCC

Used in the poster: B-hCD16A mice(CB-17 SCID) Summary: Antibody-dependent cellular cytotoxicity (ADCC) is crucial for cancer immunotherapy, primarily mediated by the CD16A receptor on human…

Read more
AACR 2024: BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts

Used in the poster: Bispecific ADC Platform Summary: A bispecific antibody-drug conjugate (bsADC), BCG033, targeting both TROP2 and PTK7, demonstrated promising preclinical efficacy in triple-negative…

Read more
AACR 2024: BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity

Used in the poster: Bispecific ADC Platform Summary: A novel bispecific antibody-drug conjugate (ADC), BCG016, targeting both 5T4 and MUC1-C antigens, was developed for solid…

Read more
AACR 2024: A novel EGFR×HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation

Used in the poster: Bispecific ADC Platform Summary: EGFR and HER3 are prevalent in epithelial tumors, particularly in lung cancer where EGFR often exhibits mutations…

Read more
AACR 2024: BCG022, a novel HER3×MET bispecific antibody-drug conjugate (bsADC), demonstrates promising anti-tumor efficacy

Used in the poster: Bispecific ADC Platform Summary: A fully human bispecific antibody (bsAb) targeting HER3 and MET was generated using RenLite® mice, known for…

Read more
Back to top